Emergent BioSolutions
EBS
£4.87
Share price
-4.13%
Change (1 day)
-57.70%
Change (1 year)
Categories
Emergent BioSolutions (EBS) - Net assets
Net assets on the balance sheet as of March 2025 : £0.41 Billion
According to Emergent BioSolutions
's latest financial reports the company has £0.41 Billion in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Emergent BioSolutions - Net assets on balance sheet (from 2004 to 2025)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2024-12-31 | $£0.38 B | -24.51% |
| 2023-12-31 | $£0.50 B | -55.57% |
| 2022-12-31 | $£1.14 B | -3.92% |
| 2021-12-31 | $£1.19 B | 12.46% |
| 2020-12-31 | $£1.06 B | 27.89% |
| 2019-12-31 | $£0.83 B | 4.23% |
| 2018-12-31 | $£0.79 B | 17.98% |
| 2017-12-31 | $£0.67 B | 39.7% |
| 2016-12-31 | $£0.48 B | 8.49% |
| 2015-12-31 | $£0.44 B | 25.35% |
| 2014-12-31 | $£0.35 B | 19.82% |
| 2013-12-31 | $£0.29 B | 8.41% |
| 2012-12-31 | $£0.27 B | 2.03% |
| 2011-12-31 | $£0.26 B | 10.8% |
| 2010-12-31 | $£0.24 B | 60.61% |
| 2009-12-31 | $£0.15 B | 10.77% |
| 2008-12-31 | $£0.13 B | 57.87% |
| 2007-12-31 | $£86.15 M | 21.87% |
| 2006-12-31 | $£70.69 M | 104.08% |
| 2005-12-31 | $£34.64 M | 189.79% |
| 2004-12-31 | $£11.95 M | |
| 2002-12-31 | $£2.59 M | -111.63% |
| 2001-12-31 | $-£22.28 Million |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Merck MRK | £36.24 B | 8,657.01% | 🇺🇸 USA |
 SIGA Technologies SIGA | £0.16 B | -60.90% | 🇺🇸 USA |
 GlaxoSmithKline GSK | £13.21 B | 3,092.00% | 🇬🇧 UK |
 Celldex Therapeutics CLDX | £0.52 B | 27.19% | 🇺🇸 USA |
 Pfizer PFE | £67.86 B | 16,298.95% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | £4.69 B | 1,034.25% | 🇮🇱 Israel |
 Soligenix SNGX | £2.7 M | -99.35% | 🇺🇸 USA |